| 1 |
NCT01887639 |
Completed |
Prevalence and Risk Factors in Unipolar Depression Patients Without Remission After One Antidepressant Trial |
- Non-psychotic Unipolar Major Depression
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Percentage of patients with unipolar major depression that do not achieve remission after one antidepressant treatment.
- Clinical, therapeutic and socio-demographic characteristics of resistant depression patients and comparisson of them with the characteristics of the sample of depressed patients in remission.
- Comparison of the depression severity change assessed by the physician with the evaluation done by the patient
|
200 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT01887639 |
NIS-NAR-XXX-2013/1 |
PANTHER |
September 2013 |
September 2014 |
September 2014 |
June 27, 2013 |
July 30, 2015 |
|
- Research Site
Buenos Aires, Argentina - Research Site
Caba, Argentina - Research Site
Chaco, Argentina - (and 5 more...)
|
|
| 2 |
NCT01426997 |
Completed |
Phenotype Depression Study |
- Major Depressive Disorder
|
|
Observational
|
|
- Emory University
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- We are using clinician administered and self report psychiatric measurements to compare relevant symptom domains in patients with major depression and increased inflammation versus patients with major depression without increased inflammation.
- We are measuring immune markers for the identification of relevant immunologic patterns of activation in patients with major depression and increased inflammation versus patients with major depression without increased inflammation.
|
279 |
All |
21 Years to 65 Years (Adult, Older Adult) |
NCT01426997 |
IRB00039107
1R01MH087604-01A1 |
|
July 2010 |
May 2016 |
May 2016 |
September 1, 2011 |
June 22, 2016 |
|
- Emory University Department of Psychiatry and Behavioral Sciences
Atlanta, Georgia, United States
|
|
| 3 |
NCT02890212 |
Recruiting |
Selenium as Augmentation Treatment for Sertraline Resistant Major Depression |
|
- Dietary Supplement: selenium supplementation
- Dietary Supplement: placebo
|
Interventional
|
Not Applicable |
- University of Sao Paulo General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hamilton Depressive Rating Scale
- Montgomery-Asberg Depression Rating Scale
- Clinical Global Impression Scale
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT02890212 |
Selen-2015 |
|
August 2005 |
December 2018 |
December 2018 |
September 7, 2016 |
May 4, 2018 |
|
- Instituto de Psiquiatria - Hcfmusp
São Paulo, Brazil
|
|
| 4 |
NCT00472576 |
Completed
Has Results |
Antidepressant Effects of NR2B in Major Depression |
|
- Drug: MK-0657
- Drug: Placebo
|
Interventional
|
Phase 1 |
- National Institute of Mental Health (NIMH)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Montgomery-Asberg Depression Rating Scale (MADRS)
- Hamilton Depression Rating Scale (HDRS)
|
5 |
All |
18 Years to 55 Years (Adult) |
NCT00472576 |
070152
07-M-0152 |
|
May 2007 |
August 2009 |
August 2009 |
May 11, 2007 |
August 3, 2012 |
April 7, 2011 |
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 5 |
NCT02209142 |
Unknown † |
Blood Biomarkers in Major Depression |
- Major Depressive Disorder
|
- Other: blood prelevement
- Other: psychometric data collection
|
Interventional
|
Not Applicable |
- Assistance Publique Hopitaux De Marseille
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- describe a transcriptional signature of the Major Depressive Episode.
- evaluate the role played by confounding factors as genetic polymorphisms,
|
275 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT02209142 |
2010-19 |
|
February 2012 |
November 2015 |
October 2016 |
August 5, 2014 |
July 27, 2016 |
|
- Assistance Publique Hopitaux de Marseille
Marseille, France
|
|
| 6 |
NCT00825799 |
Completed |
Serum Markers as a Bioassay for Unipolar Depression |
|
|
Observational
|
|
- Steward St. Elizabeth's Medical Center of Boston, Inc.
- Ridge Diagnostics Inc.
|
Other / Industry |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- Protein biomarker MDDScore.
- Score on Hamilton Depression Rating Scale (HDRS).
|
160 |
All |
18 Years to 60 Years (Adult) |
NCT00825799 |
00435 |
|
November 2007 |
May 2011 |
May 2011 |
January 21, 2009 |
January 3, 2014 |
|
- Steward St. Elizabeth's Medical Center
Boston, Massachusetts, United States
|
|
| 7 |
NCT01391221 |
Unknown † |
Inflammatory Markers and Cognitive Function in Major Depression |
|
|
Interventional
|
Phase 4 |
- Centre de recherche Fernand-Seguin, Hôpital Louis-H. Lafontaine
- Eli Lilly and Company
- Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Cognitive function measured by CANTAB
- pain inhibition
- Allostatic load
|
20 |
All |
20 Years to 50 Years (Adult) |
NCT01391221 |
2011005 |
|
July 2011 |
August 2013 |
August 2013 |
July 11, 2011 |
July 19, 2012 |
|
- Centre de Recherche Fernand Seguin
Montreal, Quebec, Canada - Hôpital Maisonneuve Rosemont
Montreal, Quebec, Canada
|
|
| 8 |
NCT00122031 |
Completed |
Deep Brain Stimulation for Treatment-Refractory Major Depression |
|
- Device: Deep Brain Stimulation with Medtronic Activa Neurostimulator
|
Interventional
|
Phase 1 |
- University Hospital, Bonn
- Medtronic
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Hamilton Depression Rating Scale (HDRS)
- Montgomery-Asberg Depression Rating Scale (MADRS)
|
13 |
All |
20 Years to 65 Years (Adult, Older Adult) |
NCT00122031 |
BSG-04-006 |
|
July 2005 |
April 2009 |
January 2011 |
July 21, 2005 |
June 14, 2012 |
|
- Department of Psychiatry and Psychotherapy, University of Bonn
Bonn, Germany
|
|
| 9 |
NCT01151982 |
Completed |
Primary Prevention of Major Depression Based on the Level and Profile of Risk of Primary Care Attenders: Cluster, Controlled, Randomised Trial |
|
- Behavioral: Psychosocial Intervention
|
Interventional
|
Not Applicable |
- The Mediterranean Institute for the Advance of Biotechnology and Health Research
- Preventive Services and Health Promotion Research Network
- Carlos III Health Institute
- Andaluz Health Service
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Prevention
|
- Accumulated incidence of major depression
- Cost-effectiveness and cost-utility
|
3326 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT01151982 |
PS09/00081 |
predictD-CCRT |
October 2010 |
July 2012 |
January 2013 |
June 29, 2010 |
November 19, 2014 |
|
- Servicio Andaluz de Salud. Distrito Sanitario Málaga
Málaga, Spain - Málaga, Spain
|
|
| 10 |
NCT01685294 |
Completed |
Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression |
- Major Depressive Disorder
|
- Behavioral: Group IPT for Depression + TAU
|
Interventional
|
Phase 3 |
- Brown University
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from Baseline in Hamilton Rating Scale for Depression (HRSD) at 3 Months
- Change from Baseline in Suicidality at 3 Months
- Change from Baseline in In-Prison Functioning at 3 Months
- (and 4 more...)
|
181 |
All |
18 Years and older (Adult, Older Adult) |
NCT01685294 |
1R01MH095230-01
R01MH095230 |
|
December 2011 |
October 2014 |
October 2014 |
September 14, 2012 |
January 13, 2016 |
|
- Massachusetts Correctional Institute - Old Colony Correctional Center
Bridgewater, Massachusetts, United States - Massachusetts Correctional Institution - Framingham
Framingham, Massachusetts, United States - South Middlesex Correctional Center
Framingham, Massachusetts, United States - (and 2 more...)
|
|
| 11 |
NCT01733654 |
Withdrawn |
Investigate Efficacy & Safety of RO4995819 vs. Placebo as Adjunct Tx in Patients w/Major Depressive Disorder |
- Depression
- Major Depressive Disorder
|
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Montgomery Asberg Depression Rating Scale
|
0 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01733654 |
23708 |
|
September 2012 |
December 2013 |
May 2014 |
November 27, 2012 |
September 12, 2013 |
|
|
|
| 12 |
NCT03670823 |
Not yet recruiting |
Prediction of SSRI Treatment in Major Depression. |
|
- Device: SIEMENS PRISMA MRI
|
Observational
|
|
- ElMindA Ltd
- Sheba Medical Center
- Hebrew University of Jerusalem
|
Industry / Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- EEG responses to cognitive tasks in combination with the Eye-tracker Device.
- Resting state connectivity analysis
- Examine correlations between the different methods
- (and 4 more...)
|
100 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03670823 |
5323-18-SMC |
|
October 1, 2018 |
October 1, 2020 |
October 1, 2020 |
September 14, 2018 |
September 14, 2018 |
|
|
|
| 13 |
NCT00361374 |
Completed
Has Results |
Safety and Effectiveness of Omega 3-Fatty Acids, EPA Versus DHA, for the Treatment of Major Depression |
- Major Depressive Disorder
|
- Dietary Supplement: eicosapentaenoic acid
- Dietary Supplement: docosahexaenoic acid
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Massachusetts General Hospital
- Cedars-Sinai Medical Center
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Score on a Depression Severity Rating Scale Over Eight Weeks
|
196 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT00361374 |
2005P002337
5R01MH074085 |
|
July 2006 |
February 2013 |
March 2013 |
August 8, 2006 |
July 18, 2014 |
July 18, 2014 |
- Depression Clinical Research Program, Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 14 |
NCT01944657 |
Withdrawn |
Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study |
- 1. Major Depressive Disorder
|
- Device: Supplemental TMS
- Drug: Standard Medication Monotherapy
|
Interventional
|
Not Applicable |
- Sheppard Pratt Health System
- Central Michigan University
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Montgomery-Åsberg Depression Rating Scale (MADRS)
- Hamilton Rating Scale for Depression (HRSD)
|
0 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01944657 |
SPHS IRB [354612-3] |
|
September 2013 |
December 2015 |
December 2015 |
September 18, 2013 |
April 25, 2017 |
|
- Sheppard Pratt Health System
Towson, Maryland, United States
|
|
| 15 |
NCT01916824 |
Completed
Has Results |
Effects of Treatment on Decision-making in Major Depression |
- Major Depressive Disorder
- Healthy Controls
|
- Drug: Any FDA Approved Antidepressant
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
|
53 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01916824 |
IRB00066705 |
|
August 2013 |
December 2015 |
December 2015 |
August 6, 2013 |
November 21, 2017 |
October 20, 2017 |
- Emory Mood and Anxiety Disorders Program
Atlanta, Georgia, United States
|
|
| 16 |
NCT01768052 |
Unknown † |
Functional Brain Imaging Study of Response to Repetitive TMS (rTMS) Treatment of Major Depression |
|
- Device: functional Near Infrared Spectroscopy
|
Observational
|
|
- Mclean Hospital
- National Alliance for Research on Schizophrenia and Depression
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Change in the connectivity strength in the CCN as assessed by fMRI
- Change in brain activation in DLPFC as assessed by fNIRS monitoring
|
40 |
All |
21 Years to 45 Years (Adult) |
NCT01768052 |
2012P002394 |
|
June 2013 |
January 2016 |
January 2016 |
January 15, 2013 |
May 4, 2015 |
|
- McLean Hospital
Belmont, Massachusetts, United States - McLean Imaging Center/McLean TMS Service
Belmont, Massachusetts, United States
|
|
| 17 |
NCT03060967 |
Not yet recruiting |
Assessment of Hedonic and Motivational States in Major Depression ( MOODDIS) |
|
- Behavioral: Computer-based tasks
|
Interventional
|
Not Applicable |
- Institut National de la Santé Et de la Recherche Médicale, France
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Screening
|
- Point of subjective equality (PSE)
- Percentage of subjective discrimination (PSD)
|
72 |
All |
18 Years to 60 Years (Adult) |
NCT03060967 |
C15-88 |
MOODDIS |
June 2017 |
September 2020 |
September 2020 |
February 23, 2017 |
May 12, 2017 |
|
|
|
| 18 |
NCT00556140 |
Completed
Has Results |
The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression |
|
|
Interventional
|
Phase 3 |
- Massachusetts General Hospital
- Bristol-Myers Squibb
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Depression and Psychosis Response Rate
- Depression and Psychosis Remission Rate
|
16 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT00556140 |
2003-P-000990 |
Abilify |
June 2003 |
January 2008 |
January 2008 |
November 9, 2007 |
August 20, 2012 |
August 20, 2012 |
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 19 |
NCT00675896 |
Completed |
A Study of Quetiapine Fumarate Sustained Release in Major Depression With Comorbid Fibromyalgia Syndrome |
|
- Drug: Quetiapine Fumarate Sustained Release
- Drug: Placebo
|
Interventional
|
Phase 4 |
- Dr Alexander McIntyre Inc.
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- last observation carried forward (LOCF) mean change from baseline to week 8 on the Hamilton Depression Scale (HAM-D) total score.
- Change from baseline to week 8 in: Brief Pain Inventory,HAM-A,CGI-S,FIQ, Sleep Scale from the Medical Outcome Study,SDS,QLES- Short Form,PHQ-15,Global Assessment Scale,Improvement (CGI-I) score from randomisation to Week 8
|
120 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00675896 |
D1443C00007 |
|
April 2007 |
June 2011 |
July 2011 |
May 12, 2008 |
July 6, 2011 |
|
- Dr. A McIntyre Inc
Penticton, British Columbia, Canada
|
|
| 20 |
NCT00419003 |
Completed
Has Results |
Research Study for Major Depressive Disorder: Investigation of Glutamate Medications |
|
- Drug: Lamotrigine
- Drug: Ketamine
- Drug: Riluzole
|
Interventional
|
Phase 4 |
- Baylor College of Medicine
- National Alliance for Research on Schizophrenia and Depression
- National Center for Research Resources (NCRR)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Montgomery-Asberg Depression Rating Scale (MARDS) Score (Acute Response to IV Ketamine in Patients With Treatment Resistant Major Depression)
- Efficacy of Lamotrigine in Decreasing IV Ketamine Psychotomimetic Side Effects
|
26 |
All |
21 Years to 70 Years (Adult, Older Adult) |
NCT00419003 |
05-0850
5M01RR000071-46 |
|
December 2006 |
July 2008 |
September 2008 |
January 5, 2007 |
March 21, 2016 |
March 21, 2016 |
- Mount Sinai School of Medicine
New York, New York, United States
|
|
| 21 |
NCT01360307 |
Completed |
Validation of the Spanish Version of the Clinically Useful Depression Outcome Scale (CUDOS) Scale |
|
|
Observational
|
|
|
Industry |
- Time Perspective: Cross-Sectional
|
- Clinically Useful Depression Outcome Scale
- Hamilton Depression Rating Scale
- SF 36
- (and 3 more...)
|
330 |
All |
18 Years and older (Adult, Older Adult) |
NCT01360307 |
NIS-NES-XXX-2011/1 |
CUDOS |
June 2011 |
November 2011 |
November 2011 |
May 25, 2011 |
December 6, 2011 |
|
- Research Site
A Coruña, Spain - Research Site
Barcelona, Spain - Research Site
Cadiz, Spain - (and 14 more...)
|
|
| 22 |
NCT00149071 |
Completed |
Transcranial Magnetic Stimulation (rTMS) Accelerates the Response to Escitalopram in Major Depression |
|
|
Interventional
|
Not Applicable |
- Hillerod Hospital, Denmark
- Medicon Valley Academy
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
|
61 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT00149071 |
1,2 |
|
March 2004 |
|
January 2006 |
September 8, 2005 |
November 5, 2007 |
|
- Psychiatric research unit, Hilleroed Hospital,
Hillerod, Denmark
|
|
| 23 |
NCT03595020 |
Active, not recruiting |
Probing Prefrontal Cortex Hemodynamic Alterations for Major Depression Disorder |
- Depressive Disorder, Major
|
|
Observational
|
|
- Xijing Hospital
- Health Science Center of Xi’an Jiaotong University
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Hamilton Depression Scale-17(HAMD-17) score alterations
- facial emotion recognition
- Pittsburgh Sleep Quality Index（PSQI）
|
200 |
All |
18 Years to 35 Years (Adult) |
NCT03595020 |
KY20172012-1 |
MDD |
February 16, 2017 |
August 31, 2018 |
December 31, 2018 |
July 23, 2018 |
July 23, 2018 |
|
- Department of psychiatry, Xijing Hospital; Research Institute of Biomedical Engineering, Xi'an Jiaotong University
Xi'an, Shaanxi, China
|
|
| 24 |
NCT01579942 |
Terminated |
Potential Use Of Brain Network Activation Analysis to Diagnose Major Depression |
- Major Depressive Disorder
|
|
Observational
|
|
- Massachusetts General Hospital
- ElMindA Ltd
|
Other / Industry |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Brain Network Analysis group patterns
- Identify possible predictors of treatment response
|
70 |
All |
18 Years to 55 Years (Adult) |
NCT01579942 |
2011P000200 |
|
April 2012 |
|
|
April 18, 2012 |
March 6, 2017 |
|
- Depression Clinical and Research Program
Boston, Massachusetts, United States
|
|
| 25 |
NCT01027559 |
Completed
Has Results |
fMRI Study of Treatment Changes in Major Depression |
- Major Depression
- Treatment
|
- Drug: Sertraline
- Behavioral: Cognitive Behavioral Therapy
|
Interventional
|
Not Applicable |
- Washington University School of Medicine
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Other
|
- Blood Oxygen-level Dependent Activations During an Emotional Distractor Task Between fMRI Scans of Depressed Participants in the CBT Group and Control Participants.
- Hamilton Depression Rating Scale Score at Baseline and 12 Weeks
|
97 |
All |
18 Years to 50 Years (Adult) |
NCT01027559 |
081348
R01MH064821
2R01MH064821-05A2
DDTR A3-NSI |
|
February 2009 |
January 2014 |
January 2014 |
December 8, 2009 |
July 17, 2018 |
June 13, 2018 |
- Washington University
Saint Louis, Missouri, United States
|
|
| 26 |
NCT02245373 |
Unknown † |
Cost-effectiveness of a Non-Pharmacological Treatment (Active Monitoring) vs. a Pharmacological Treatment for Major Depression in Primary Care. |
- Mild to Moderate Depression.
|
- Drug: Antidepressants
- Other: Active Monitoring
|
Observational
|
|
- Fundació Sant Joan de Déu
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- Compare the cost-effectiveness of active monitoring (standard treatment without antidepressants) vs antidepressants in mild major depression taking into account the severity and disability in Primary Care. The changes at Time Frame will be assessed.
- 1.Quality of life of patients with major depression who initiate treatment in Primary Care.
- 2. Cost-utility of an antidepressant vs no treatment in mild Depression in Primary.
|
263 |
All |
18 Years and older (Adult, Older Adult) |
NCT02245373 |
Infap |
|
June 2013 |
July 2014 |
July 2015 |
September 19, 2014 |
September 19, 2014 |
|
|
|
| 27 |
NCT00517036 |
Completed |
Omega-3 Fatty Acids for Treating Adults With Major Depression |
|
- Dietary Supplement: EPA omega-3 fatty acid
- Dietary Supplement: DHA omega-3 fatty acid
- Dietary Supplement: Placebo comparator
|
Interventional
|
Phase 3 |
- Cedars-Sinai Medical Center
- National Institute of Mental Health (NIMH)
- Massachusetts General Hospital
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Depression rating scale score on HAM-D 17, SCID Mood Module
|
196 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT00517036 |
R01MH073765
DATR A5-ETMA |
|
July 2006 |
January 2011 |
January 2011 |
August 16, 2007 |
April 4, 2013 |
|
- Cedars-Sinai Medical Center
Los Angeles, California, United States
|
|
| 28 |
NCT03228953 |
Recruiting |
Pharmacogenomic Testing in Major Depressive Disorder |
- Major Depressive Disorder
|
- Other: Pharmacogenomic testing
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Health Services Research
|
- Score on the Hamilton Rating Scale for Depression (HAMD-17)
- Score on Subject-Rated 16-item Quick Inventory of Depression Symptomatology Scales (QIDS-SR)
- Score on the 9-item Patient Health Questionnaire (PHQ-9)
|
206 |
All |
21 Years to 80 Years (Adult, Older Adult) |
NCT03228953 |
AAAR4283 |
|
August 2017 |
May 15, 2021 |
May 15, 2021 |
July 25, 2017 |
August 4, 2017 |
|
- Columbia University Medical Center
New York, New York, United States
|
|
| 29 |
NCT00286546 |
Completed |
Testosterone and Major Depression |
|
|
Observational
|
|
- University Health Network, Toronto
|
Other |
- Observational Model: Defined Population
- Observational Model: Natural History
- Time Perspective: Cross-Sectional
- Time Perspective: Prospective
|
|
100 |
Male |
40 Years to 65 Years (Adult, Older Adult) |
NCT00286546 |
002 |
|
January 2001 |
|
August 2005 |
February 3, 2006 |
September 11, 2006 |
|
- Toronto Western Hospital
Toronto, Ontario, Canada
|
|
| 30 |
NCT00159146 |
Terminated |
Trial of Pindolol Augmentation in Venlafaxine Treated Patients With Major Depression |
|
- Drug: Pindolol and venlafaxin
|
Interventional
|
Not Applicable |
- Hillerod Hospital, Denmark
- Wyeth is now a wholly owned subsidiary of Pfizer
- Tvergaards Foundation
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Hamilton Depression Rating Scale scores
- Preskorn scores
|
31 |
All |
18 Years and older (Adult, Older Adult) |
NCT00159146 |
version 5 |
|
August 2002 |
|
September 2007 |
September 12, 2005 |
December 27, 2007 |
|
- Psychiatric Research Unit, Hillerod Hospital
Hillerod, Denmark
|
|
| 31 |
NCT00208702 |
Completed |
Thyroid Medication and Antidepressants for Treating Major Depression |
|
- Drug: Triiodothyronine
- Other: Placebo
- Drug: Sertraline
|
Interventional
|
Phase 4 |
- Emory University
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
|
153 |
All |
18 Years to 60 Years (Adult) |
NCT00208702 |
0431-1996
R01MH056946
431-1996
DSIR AT-SO |
|
September 1996 |
July 2003 |
July 2003 |
September 21, 2005 |
November 17, 2015 |
|
- Emory University
Atlanta, Georgia, United States
|
|
| 32 |
NCT02165449 |
Recruiting |
Biomarkers of Fast Acting Therapies in Major Depression |
- Major Depressive Disorder
|
|
Interventional
|
Phase 1 |
- University of California, Los Angeles
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in the Hamilton Depression Rating Scale measured between baseline and 24 hrs following the first ketamine infusion treatment, and 24 hrs following up to three additional ketamine infusions
- Change in the Hamilton Depression Rating Scale measured between the last ketamine infusion treatment and 5 week follow-up
- Change in gene expression measured between baseline and 24 hrs following the first ketamine infusion treatment, and 24 hrs following up to three additional ketamine infusions
- (and 7 more...)
|
60 |
All |
18 Years to 64 Years (Adult) |
NCT02165449 |
HS001796
K24MH102743
U01MH110008 |
|
June 2014 |
August 2020 |
August 2021 |
June 17, 2014 |
August 28, 2018 |
|
- Geffen School of Medicine, UCLA
Los Angeles, California, United States
|
|
| 33 |
NCT01421342 |
Completed
Has Results |
VA Augmentation and Switching Treatments for Improving Depression Outcomes |
- Major Depressive Disorder
|
- Drug: Switching: Bupropion-SR
- Drug: Augmenting: Antidepressant + Bupropion-SR
- Drug: Augmenting: Antidepressant + Aripiprazole
|
Interventional
|
Phase 3 |
- VA Office of Research and Development
|
U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate of Protocol Remission of Symptoms of Major Depressive Disorder
- Rate of Protocol Relapse of Symptoms of Major Depression After Achieving Remission in the Acute Phase
- Rate of Protocol Response as Reduction in Symptoms of Major Depression (>= 50% Reduction in QIDS-C)
- Rate of Protocol Response Measured as a Change in Clinical Global Impression (CGI) - Improvement Scale
|
1522 |
All |
18 Years and older (Adult, Older Adult) |
NCT01421342 |
576 |
VAST-D |
December 2012 |
August 2015 |
June 2016 |
August 22, 2011 |
May 28, 2018 |
May 28, 2018 |
- Tuscaloosa VA Medical Center, Tuscaloosa, AL
Tuscaloosa, Alabama, United States - Phoenix VA Health Care System, Phoenix, AZ
Phoenix, Arizona, United States - Southern Arizona VA Health Care System, Tucson
Tucson, Arizona, United States - (and 32 more...)
|
|
| 34 |
NCT01754493 |
Completed
Has Results |
Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression |
- Major Depression
- Irritable Bowel Syndrome
|
|
Interventional
|
Phase 4 |
- New York State Psychiatric Institute
- Eli Lilly and Company
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Montgomery-Asberg Depression Rating Scale (MADRS)
- Gastrointestinal Symptoms Rating Scale (GSRS)
- Clinician-Rated Global Impression Scales (CGI)
- (and 2 more...)
|
17 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01754493 |
#6479R
F1J-US-X037 |
IBS-MDD |
December 2008 |
December 2014 |
December 2014 |
December 21, 2012 |
November 25, 2016 |
November 25, 2016 |
- New York State Psychiatric Institute, 1051 Riverside Drive
New York, New York, United States
|
|
| 35 |
NCT00220623 |
Unknown † |
Efficacy of 18-Months of Antidepressive Medication Plus CBT or Dynamic or Supportive Psychotherapy for Recurrent Major Depression |
|
- Drug: antidepressant medications, flexible drug choice
- Behavioral: CBT, Psychodynamic or Supportive Psychotherapy
|
Interventional
|
Phase 3 |
- Sir Mortimer B. Davis - Jewish General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single
- Primary Purpose: Treatment
|
- Time to recovery of major depressive episode
- Time to recurrence of major depression, once recovered
- improvement in depressive defenses
- (and 3 more...)
|
30 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00220623 |
#04-013 |
|
August 2004 |
|
|
September 22, 2005 |
September 22, 2005 |
|
- Institute of Community and Family Psychiatry
Montreal, Quebec, Canada
|
|
| 36 |
NCT00510822 |
Completed |
Cimicoxib for the Treatment of Major Depression (SECIM) |
|
- Drug: Cimicoxib
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Affectis Pharmaceuticals AG
- FGK Clinical Research GmbH
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- • Mean change on the total score of the Hamilton Depression Rating Scale (HamD-17) from baseline to endpoint (Week 6).
- • Changes from baseline to interim weekly visits (week 1 to 5) in HamD-17 score • Clinical Global Impression (CGI) score • Montgomery Asberg Depression Rating Scale (MADRS) score • Response rate, remission rate and drop out rate. • Onset of
|
169 |
All |
18 Years to 60 Years (Adult) |
NCT00510822 |
AFX-01
EudraCT-No. 2007-001335-54 |
|
October 2007 |
February 2010 |
February 2010 |
August 2, 2007 |
November 13, 2013 |
|
- Landeskrankenhaus Klagenfurt, Abteilung für Psychiatrie und Psychotherapie
Klagenfurt, Austria - Gemeinnützige Salzburger Landeskliniken Betriebsgesellschaft mbH
Salzburg, Austria - Faculty Hospital Brno
Brno, Czech Republic - (and 22 more...)
|
|
| 37 |
NCT01741142 |
Terminated |
Efficacy and Safety Study of ABT-436 in Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: ABT-436
- Drug: Escitalopram
- Drug: Placebo
|
Interventional
|
Phase 2 |
- AbbVie (prior sponsor, Abbott)
- AbbVie
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Primary efficacy variable will be change from baseline to Week 6 visit on Montgomery-Asberg Depression Rating Scale (MADRS) total score.
- Secondary efficacy variables include change from Baseline to Week 6 on clinician-rated Hamilton Depression Rating Scale.
|
19 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01741142 |
M11-733 |
|
January 2012 |
October 2013 |
August 2015 |
December 4, 2012 |
October 8, 2013 |
|
- Site Reference ID/Investigator# 85593
Little Rock, Arkansas, United States - Site Reference ID/Investigator# 87228
Garden Grove, California, United States - Site Reference ID/Investigator# 87214
National City, California, United States - (and 15 more...)
|
|
| 38 |
NCT03421847 |
Completed |
Study of Rotatory Vestibular Tests in Major Depression Patients and Healthy Control Subjects. |
- Depression
- Vestibular Disorder
|
- Diagnostic Test: Rotatory vestibular test
|
Observational
|
|
- Vest Brain,Centro de Estudios Neurovestibulares
- Centro de Medicina Aeroespacial.
|
Other |
- Observational Model: Case-Control
- Time Perspective: Other
|
|
41 |
All |
18 Years and older (Adult, Older Adult) |
NCT03421847 |
ROTDEPR01 |
|
July 1, 2005 |
December 15, 2006 |
December 15, 2006 |
February 5, 2018 |
February 6, 2018 |
|
|
|
| 39 |
NCT00445237 |
Completed |
Evaluation of Deep Transcranial Magnetic Stimulation (TMS) H-Coil in the Treatment of Major Depression |
|
- Device: H1 and H2 deep TMS coils
|
Interventional
|
Phase 1 |
- Shalvata Mental Health Center
- Brainsway
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
|
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00445237 |
SH-505 |
|
May 2006 |
|
March 2008 |
March 8, 2007 |
February 5, 2009 |
|
- Shalvata MHC
Hod Hasharon, Israel
|
|
| 40 |
NCT01473381 |
Completed
Has Results |
Safety and Efficacy of Vilazodone in Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Vilazodone
- Drug: Placebo to citalopram
- Drug: Placebo to vilazodone
- Drug: Citalopram
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 10
- Change From Baseline to Week 10 in the Clinical Global Impressions-Severity (CGI-S) Scale Score
- Percentage of Participants With a Montgomery-Åsberg Depression Rating Scale (MADRS) Sustained Response
|
1162 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01473381 |
VLZ-MD-01 |
VLZ-MD-01 |
December 2011 |
June 2013 |
June 2013 |
November 17, 2011 |
August 8, 2014 |
August 8, 2014 |
- Forest Investigative Site 036
Birmingham, Alabama, United States - Forest Investigative Site 016
Dothan, Alabama, United States - Forest Investigative Site 033
Scottsdale, Arizona, United States - (and 51 more...)
|
|
| 41 |
NCT01473394 |
Completed
Has Results |
Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Dose-matched placebo
- Drug: Vilazodone
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 8
- Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Score at Week 8
- Percentage of Participants With a Montgomery-Åsberg Depression Rating Scale (MADRS) Sustained Response Rate
|
518 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01473394 |
VLZ-MD-03 |
|
December 2011 |
February 2013 |
February 2013 |
November 17, 2011 |
April 3, 2014 |
April 3, 2014 |
- Forest Investigative Site 009
Beverly Hills, California, United States - Forest Investigative Site 003
Encino, California, United States - Forest Investigative Site 010
New port Beach, California, United States - (and 11 more...)
|
|
| 42 |
NCT03347487 |
Recruiting |
Deep Brain Stimulation of the Bilateral Habenula for Treatment- Resistant Major Depression |
- Treatment Resistant Major Depression Disorder
|
- Procedure: Surgical Intervention
- Device: Shame DBS device followed by active DBS
- Device: Active DBS device followde by shame DBS
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- changes in the Hamilton Depression Scale(HAMD-17)
- changes in the Montgomery-Asberg Depression Rating Scale
- changes in the brain activity
- (and 4 more...)
|
6 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03347487 |
Habenula |
|
November 13, 2017 |
November 30, 2018 |
November 30, 2018 |
November 20, 2017 |
March 2, 2018 |
|
- Shanghai Ruijin Hospital Functional Neurosurgery
Shanghai, Shanghai, China
|
|
| 43 |
NCT01778790 |
Completed |
Deep Brain Stimulation of the Superolateral Branch of the Medial Forebrain Bundle (slMFB) for the Treatment of Refractory Major Depression |
|
- Device: Deep Brain Stimulation with Activa PC Multi-program Neurostimulator
|
Interventional
|
Phase 2 |
- University Hospital, Bonn
|
Other |
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Depression Severity assessed with Montgomery Asberg Depression Scale (MADRS)
- Depression Severity rated with Hamilton Depression Rating Scale (HDRS24)
|
16 |
All |
20 Years to 75 Years (Adult, Older Adult) |
NCT01778790 |
BSG-13-2319DBS |
FORESEEII |
July 2013 |
February 2016 |
January 2018 |
January 29, 2013 |
August 7, 2018 |
|
- University Hospital Bonn
Bonn, Germany
|
|
| 44 |
NCT00613912 |
Completed |
Advanced MRI in Major Depression |
- Depressive Disorder, Major
|
- Other: Magnetic Resonance Imaging
|
Observational
|
|
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Differences in morphological and functional cerebral MRI findings in patients suffering from major depression
|
49 |
All |
20 Years to 65 Years (Adult, Older Adult) |
NCT00613912 |
AUFF-2005-740-004 |
|
March 2008 |
December 2009 |
June 2011 |
February 13, 2008 |
November 21, 2011 |
|
- Aalborg Hospital / Aarhus University Hospital
Aalborg, Jutland, Denmark
|
|
| 45 |
NCT01824433 |
Completed |
Comparison of Venlafaxine and Fluoxetine in the Treatment of Postmenopausal Women With Major Depression |
|
- Drug: venlafaxine
- Drug: fluoxetine
|
Interventional
|
Phase 4 |
- Capital Medical University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Overall Improvement
- Improvement of individual symptoms
|
189 |
Female |
50 Years to 80 Years (Adult, Older Adult) |
NCT01824433 |
VFPWMDD |
|
March 7, 2013 |
March 16, 2017 |
March 16, 2017 |
April 4, 2013 |
September 14, 2017 |
|
- Beijing Anding Hospital
Beijing, Beijing, China
|
|
| 46 |
NCT03623724 |
Recruiting |
iCare4Depression: Effectiveness of a Blended Cognitive-Behavioral Therapy in Routine Practice |
|
- Behavioral: blended Cognitive-behavioral Therapy
- Other: Treatment-As-Usual
|
Interventional
|
Not Applicable |
- University Institute of Maia
- INESC TEC
- University of Limerick
- (and 3 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in depressive symptoms from baseline to 52 weeks after baseline
- Change in the diagnosis of major depression disorder from baseline to 52 weeks after baseline
- Change in the general clinical outcome from baseline to 52 weeks after baseline
- (and 8 more...)
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT03623724 |
PTDC/MHC-PCL/1991/2014 |
iCare4Dep |
December 2, 2017 |
September 30, 2018 |
June 30, 2019 |
August 9, 2018 |
August 9, 2018 |
|
- University Institute of Maia
Maia, Porto, Portugal
|
|
| 47 |
NCT00229645 |
Completed |
A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and of Quetiapine Fumarate (Seroquel®) as Potentiation SSRI's, and SNRI's Treatment in Major Depression With Anxiety |
- Major Depression With Comorbid Anxiety Symptoms
|
- Drug: Quetiapine Fumarate (Seroquel®)
|
Interventional
|
Phase 4 |
- Dr Alexander McIntyre Inc.
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- To compare the efficacy of quetiapine versus placebo over 8 weeks as an adjunctive agent for unipolar non-psychotic adult outpatients on SSRI or SNRI therapy with residual symptoms of depression and comorbid anxiety symptoms. This will be measured by the
- 1. Hamilton Depression Scale (HAM-D) total score,
- 2. Hamilton Anxiety Scale (HAM-A) total score
|
60 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00229645 |
D1441C00017 |
|
November 2003 |
|
April 2005 |
September 30, 2005 |
July 13, 2016 |
|
- Dr. A. McIntyre
Penticton, British Columbia, Canada
|
|
| 48 |
NCT01611818 |
Completed |
Low Intensity Versus Self-guided Internet-delivered Psychotherapy for Major Depression |
|
- Other: Low Intensity Internet-delivered psychotherapy
- Other: Self-guided Internet delivered psychotherapy
- Other: Improved treatment as usual
|
Interventional
|
Not Applicable |
- Javier Garcia Campayo
- Carlos III Health Institute
- Hospital Miguel Servet
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Severity of depressive symptomatology measured by Beck Depression Inventory II
- Socio-demographic variables.
- Mini-International Neuropsychiatric Interview (MINI).
- (and 5 more...)
|
300 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01611818 |
PI10/01083 |
|
September 2012 |
December 2014 |
December 2016 |
June 5, 2012 |
August 10, 2017 |
|
- Hospital Parc Sanitari Sant Joan de Deu
Sant Boi de Llobregat, Barcelona, Spain - Health Science Research Institute, University Balearic Islands
Palma de Mallorca, Mallorca, Spain - Psychiatric Service. Hospital Vall D'Hebrón
Barcelona, Spain - (and 3 more...)
|
|
| 49 |
NCT00285766 |
Completed |
Safety, Tolerability and Efficacy of the Transdermal System in Elderly Subjects With Major Depression |
|
- Drug: Selegiline Transdermal System
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
300 |
All |
65 Years and older (Older Adult) |
NCT00285766 |
S9303-P0204 |
|
August 2002 |
|
July 2005 |
February 2, 2006 |
April 22, 2008 |
|
- Mohammed Bari, M.D.
Chula Vista, California, United States - Charles Meredith, M.D.
San Diego, California, United States - Daniel Zimbroff, M.D.
Upland, California, United States - (and 12 more...)
|
|
| 50 |
NCT00464711 |
Completed
Has Results |
Brain GABA Levels and Treatment Response in Major Depressive Disorder |
- Major Depressive Disorder
|
|
Interventional
|
Phase 4 |
- Massachusetts General Hospital
- Mclean Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response and Remitter Status at Endpoint, Based on Change in Depression Severity Rating Scores
|
40 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00464711 |
2006-P-001295 |
|
September 2006 |
September 2009 |
September 2009 |
April 24, 2007 |
January 4, 2017 |
January 4, 2017 |
- Depression Clinical and Research Program, Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 51 |
NCT03000530 |
Completed |
A Study to Evaluate SAGE-217 in Subjects With Moderate to Severe Major Depressive Disorder |
|
- Drug: SAGE-217
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Safety and tolerability, as assessed by adverse events [Part A]
- Safety and tolerability, as assessed by clinical laboratory measures [Part A]
- Safety and tolerability, as assessed by vital signs [Part A]
- (and 9 more...)
|
102 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03000530 |
217-MDD-201 |
|
December 2016 |
October 4, 2017 |
October 31, 2017 |
December 22, 2016 |
October 5, 2018 |
|
- Sage Investigational Site
Garden Grove, California, United States - Sage Investigational Site
Orlando, Florida, United States - Sage Investigational Site
Atlanta, Georgia, United States - (and 5 more...)
|
|
| 52 |
NCT03230682 |
Recruiting |
Eealy Improvement Predicts Antidepressants Response in Adults With Major Depression Disorder |
- Major Depressive Disorder
|
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Early improvement
- Response
|
80 |
All |
16 Years to 55 Years (Child, Adult) |
NCT03230682 |
KY2017-01 |
|
July 25, 2017 |
June 11, 2018 |
July 11, 2018 |
July 26, 2017 |
July 26, 2017 |
|
- Dept. of Neurology, Huashan Hospital, Fudan University
Shanghai, Shanghai, China
|
|
| 53 |
NCT00770783 |
Completed |
Magnetic Seizure Therapy (MST) for Treatment Resistant Major Depression |
|
- Device: Thymatron
- Device: Tonica MagPro MST
|
Interventional
|
Phase 3 |
- University Hospital, Bonn
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Clinical improvement (Hamilton Rating Scale for Depression)
- Clinical improvement (Montgomery- Åsberg Rating Scale for Depression)
|
30 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00770783 |
BSG-05-001 |
|
February 2005 |
September 2013 |
May 2014 |
October 10, 2008 |
August 6, 2018 |
|
- Department of Psychiatry and Psychotherapy - University Hospital
Bonn, Germany
|
|
| 54 |
NCT00461279 |
Completed |
Attachment Security as Mediator and Moderator of Outcome in Major Depression |
|
- Behavioral: Cognitive Behavior Therapy
- Behavioral: Interpersonal Psychotherapy
|
Interventional
|
Not Applicable |
- Centre for Addiction and Mental Health
- Ontario Mental Health Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
134 |
All |
18 Years and older (Adult, Older Adult) |
NCT00461279 |
165/2006 |
|
August 2006 |
February 2010 |
March 2010 |
April 17, 2007 |
December 6, 2011 |
|
- Centre for Addiction and Mental Health
Toronto, Ontario, Canada
|
|
| 55 |
NCT03328819 |
Recruiting |
Therapeutic Effect and Mechanism of Acupuncture Treating Chronic Pain and Major Depression Comorbidity |
|
|
Interventional
|
Not Applicable |
- China Medical University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The change of Hamilton Rating Scale for Depression (HAMD)
- The change of Brief Pain Inventory (BPI)
- The change of Beck Depressive Inventory (BDI-II)
- (and 13 more...)
|
75 |
All |
20 Years to 65 Years (Adult, Older Adult) |
NCT03328819 |
CMUH106-REC1-077 |
|
August 1, 2017 |
July 31, 2018 |
July 31, 2020 |
November 1, 2017 |
November 1, 2017 |
|
- China Medical University Hospital
Taichung, Taiwan
|
|
| 56 |
NCT03514810 |
Completed |
Combined Sertraline and Ketoprofen Administration in Major Depressive Disorder |
- Major Depressive Disorder
|
- Combination Product: Combined Sertraline & Ketoprofen
- Other: Interleukins in MDD after treatment
|
Interventional
|
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Reduction in the Beck Depression Inventory-II Score
- Decrease in Serum of IL-1β, IL-6, and IL-18 Levels
- Body mass index (BMI)
|
28 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03514810 |
KufaU
Arafataldujaili |
Srt+ktpMDD |
January 10, 2017 |
September 10, 2017 |
December 31, 2017 |
May 2, 2018 |
May 2, 2018 |
|
|
|
| 57 |
NCT01182103 |
Completed
Has Results |
Epigenetic Regulation of BDNF in Major Depression |
- Major Depressive Disorder
|
|
Observational
|
|
- Chang Gung Memorial Hospital
|
Other |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- Brain-derived Neurotrophic Factor (BDNF) DNA Methylation of Major Depressive Disorder (MDD) Patients and Healthy Controls
- Histone Modification of MDD Patients Before and After Treatment and With Healthy Controls
- BDNF Levels of MDD Patients Before and After Treatment and Healthy Controls
|
110 |
All |
18 Years to 60 Years (Adult) |
NCT01182103 |
NSC99-2628-B-182-002-MY2 |
|
August 2010 |
July 2012 |
May 2013 |
August 16, 2010 |
August 15, 2014 |
August 15, 2014 |
- Department of Psychiatry, Chang Gung Memorial Hospital
Kaohsiung, Taiwan
|
|
| 58 |
NCT01200901 |
Completed |
Quetiapine in Melancholic Depression |
|
|
Interventional
|
Phase 4 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- quetiapine XR treatment will be effective and safe for patients with major depression with melancholic features
- normalization of limbic areas associated with increased salivary cortisol response to a stressful task
- successful treatment with quetiapine XR will be associated with normalization of the salivary cortisol response to the stressful math task
|
20 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01200901 |
Nelson AZ-IIT |
|
September 2008 |
September 2012 |
September 2012 |
September 14, 2010 |
January 18, 2013 |
|
- University of Cincinnati
Cincinnati, Ohio, United States
|
|
| 59 |
NCT02139540 |
Unknown † |
Nitrous Oxide as Treatment for Major Depression - a Pilot Study |
- Depression
- Major Depressive Disorder
|
- Drug: Nitrous Oxide
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Washington University School of Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in HDRS-21 (21-point Hamilton Depression Rating Scale)
- Change in QIDS -SR [Quick Inventory of Depressive Symptomatology - Self Report]
- Clinical Depression Endpoints
- Change in Plasma Total Homocysteine
|
40 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02139540 |
201204023 |
|
November 2012 |
December 2016 |
December 2016 |
May 15, 2014 |
January 14, 2016 |
|
- Barnes-Jewish Hospital
St. Louis, Missouri, United States
|
|
| 60 |
NCT02149836 |
Completed |
Study to Treat Major Depressive Disorder (MDD) With a New Medication |
- Major Depressive Disorder
- Depression
|
|
Interventional
|
Phase 2 |
- Icahn School of Medicine at Mount Sinai
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Montgomery-Asberg Depression Rating Scale comparison to baseline
- Patient Rated Inventory of Side Effects (PRISE)
- Columbia-Suicide Severity Rating Scale (C-SSRS)
- Functional MRI comparison to baseline
|
18 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02149836 |
GCO 14-0597 |
|
August 2014 |
December 2016 |
December 2016 |
May 29, 2014 |
December 21, 2016 |
|
- Icahn School of Medicine at Mount Sinai
New York, New York, United States
|
|
| 61 |
NCT00531947 |
Completed
Has Results |
Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression |
- Major Depressive Disorder
|
- Drug: Selegiline Transdermal System
- Drug: Placebo
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- CDRS-R Total Score (Child) (mITT w/LOCF Population) Week 12
- CGI-S - Week 12 (mITT w/LOCF Population)
- CGI-C - Week 12 (mITT w/LOCF Population)
- (and 16 more...)
|
308 |
All |
12 Years to 17 Years (Child) |
NCT00531947 |
S9303-P0605 |
|
July 2007 |
October 2010 |
October 2010 |
September 19, 2007 |
January 15, 2014 |
June 26, 2013 |
- Dr. Nelson Handal
Dothan, Alabama, United States - Dr. Mohammed Bari
National City, California, United States - Dr. Michael McManus
SanDiego, California, United States - (and 17 more...)
|
|
| 62 |
NCT00611052 |
Terminated |
Prevention of Adolescent Major Depression |
|
- Behavioral: the Adolescent Coping with Stress
- Behavioral: Treatment as usual
- Other: usual health education
|
Interventional
|
Not Applicable |
- National Institute for Health and Welfare, Finland
- Helsinki University
- University of Eastern Finland
- (and 4 more...)
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Prevention
|
- Major depression (diagnostic interview) High level of depressive symptoms (self-report scale)
- Suicidality (diagnostic interview, self-report scale)
|
65 |
All |
14 Years to 16 Years (Child) |
NCT00611052 |
KTL423-0 |
CWSA-Fin |
March 2008 |
December 2013 |
December 2013 |
February 8, 2008 |
April 20, 2016 |
|
- Kuopio University Hospital and Kuopio University
Kuopio, Finland - Turku Primary Health care and Adolescent Psychiatric clinic
Turku, Finland - Vantaa Primary Health Care
Vantaa, Finland
|
|
| 63 |
NCT00168272 |
Completed |
Priming rTMS In Major Depression |
- Major Depressive Disorder
|
- Device: Transcranial Magnetic Stimulation
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- The primary outcome measure used is the MADRS (Montgomery-Asberg Depression Rating Scale). At study end response criteria is defined as a 50% reduction in total MADRS score and remission defined as less or equal to 10.
- Other outcome measures administered fortnightly are: BPRS (Brief Psychiatric Rating Scale), CORE (measure of melancholic symptoms), BDI (Beck Depression Inventory), CGI (Clinical Global Impression Scale), GAF (Global Assessment of Functioning Scale).
|
100 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT00168272 |
5/04 |
|
June 2004 |
|
March 2007 |
September 15, 2005 |
April 16, 2007 |
|
- Alfred Psychiatry Research Centre
Melbourne, Victoria, Australia
|
|
| 64 |
NCT00715559 |
Terminated
Has Results |
Cysteamine Therapy for Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: cysteamine bitartrate
|
Interventional
|
Not Applicable |
- Icahn School of Medicine at Mount Sinai
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Montgomery-Åsberg Depression Rating Scale (MADRS)
- Clinical Global Impression Scales for Severity (CGI-S) and Improvement (CGI-I)
- Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16)
- Systematic Assessment for Treatment Emergent Effects (SAFTEE)
|
3 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00715559 |
GCO # 07-0478 |
|
July 2008 |
May 2009 |
May 2009 |
July 15, 2008 |
April 7, 2017 |
June 16, 2011 |
- Mount Sinai School of Medicine
New York, New York, United States
|
|
| 65 |
NCT03295708 |
Recruiting |
Fish Oil as Adjunct Treatment for Major Depressive Disorder |
- Major Depressive Disorder
|
- Dietary Supplement: fish oil capsule
- Dietary Supplement: soybean oil capsule
|
Interventional
|
Not Applicable |
- Second Xiangya Hospital of Central South University
- Xiangya Hospital of Central South University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Changes in Hamilton Depression Scale (HAMD) HAMD
- Changes in Clinical Global Impression (CGI)
- Changes in Hamilton Anxiety Scale (HAMA)
- (and 2 more...)
|
120 |
All |
18 Years to 50 Years (Adult) |
NCT03295708 |
MDD201610 |
|
October 1, 2017 |
October 1, 2019 |
April 1, 2020 |
September 28, 2017 |
October 10, 2017 |
|
- Mental Health Institute, Second Xiangya Hospital of Central South University
Changsha, Hunan, China
|
|
| 66 |
NCT03254017 |
Recruiting |
Remotely Programmed Deep Brain Stimulation of the Bilateral Habenula for Treatment- Resistant Major Depression: An Open Label Pilot Trial |
- Treatment Resistant Major Depressive Disorder
|
- Procedure: Bilateral surgical implantation of DBS system to Habeluna
- Other: Follow-up Period
|
Interventional
|
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in the Montgomery-Asberg Depression Rating Scale
- Change in the Hamilton Depression Scale
- Change in the Hamilton Anxiety Scale
- (and 5 more...)
|
6 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03254017 |
Habenula DBS |
|
July 24, 2017 |
July 30, 2018 |
August 30, 2019 |
August 18, 2017 |
May 18, 2018 |
|
- Shanghai Ruijin Hospital Functional Neurosurgery
Shanghai, Shanghai, China - Shanghai Ruijin Hospital Functional Neurosurgery
Shanghai, Shanghai, China
|
|
| 67 |
NCT00086307 |
Completed
Has Results |
Lexapro and Pramipexole and to Treat Major Depression |
|
- Drug: Pramipexole
- Drug: Escitalopram
|
Interventional
|
Phase 2 |
- National Institute of Mental Health (NIMH)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Montgomery Asberg Depression Rating Scale (MADRS)
|
39 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00086307 |
040227
04-M-0227 |
|
June 2004 |
March 2010 |
March 2010 |
June 30, 2004 |
January 28, 2013 |
July 12, 2012 |
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 68 |
NCT00463580 |
Completed
Has Results |
A Study of Infliximab for Treatment Resistant Major Depression |
|
- Drug: infliximab (remicade)
- Drug: Placebo
|
Interventional
|
Phase 4 |
- Emory University
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- (Study Endpoint): Mean (SD) Hamilton Depression Rating Scale 17-item (HAM-D-17) Scores at Baseline and Each Post Baseline Time Point.
- Number of Patients With a 50% Reduction in HDRS Scores at Any Study Point
- Between Group Difference in Percentage of Remitted Patients During Treatment (HDRS ≤7 or CGI of 1)
- (and 5 more...)
|
60 |
All |
25 Years to 60 Years (Adult) |
NCT00463580 |
IRB00011734
1R21MH077172-01A2 |
Infliximab |
November 2008 |
June 2011 |
June 2011 |
April 20, 2007 |
March 29, 2018 |
May 12, 2014 |
|
|
| 69 |
NCT01625546 |
Completed |
Whole Body Hyperthermia and Major Depression (MDD) |
- Depressive Disorder, Major
|
- Device: Whole Body Hyperthermia system
|
Interventional
|
Not Applicable |
- University of Arizona
- Dr. med. h.c. Erwin Braun Foundation
- The Depressive and Bipolar Disorder Alternative Treatment Foundation
- Brain & Behavior Research Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- 17-item Hamilton Rating Scale for Depression (HAM-D; derived from the 31-item instrument)
- Change in QIDS (Quick Inventory of Depressive Symptoms) Score from baseline response
- Core body temperature monitoring
- (and 6 more...)
|
34 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01625546 |
12-0147-01 |
|
July 2012 |
May 2015 |
May 2015 |
June 21, 2012 |
August 10, 2015 |
|
- University of Arizona
Tucson, Arizona, United States
|
|
| 70 |
NCT00326677 |
Unknown † |
Primary Prevention of Major Depression in Later Life |
|
- Behavioral: Problem Solving Therapy
- Behavioral: Dietary Education
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- BDI, Hamilton, FDI scores, SCID diagnosis of major depression
- CES-D, ISEL,Folstein Mini-Mental, MOS-SF8,BSI, EXIT, Hopkins Verbal Learning Test, PTSD Checklist, Social Problem Solving Inventory, PSQI, CIRS-G, RAND 12
|
306 |
All |
50 Years and older (Adult, Older Adult) |
NCT00326677 |
0601117 |
|
May 2006 |
June 2012 |
December 2013 |
May 17, 2006 |
February 18, 2011 |
|
- University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States - University of Pittsburgh
Pittsburgh, Pennsylvania, United States
|
|
| 71 |
NCT01095263 |
Completed |
Effects of Deep Brain Stimulation in Treatment Resistant Major Depression |
|
- Device: DBS
- Device: No Stimulation (Sham)
|
Interventional
|
Phase 1 |
- University Hospital, Bonn
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Depression Severity assessed with Montgomery Asberg Depression Scale (MADRS)
- Depression Severity rated with Hamilton Depression Rating Scale (HDRS24)
- Adverse Event Schedule
- Comprehensive neuropsychological test battery
|
7 |
All |
20 Years to 70 Years (Adult, Older Adult) |
NCT01095263 |
BSG-10-4711DBS |
FORESEE |
April 2011 |
August 2012 |
January 2013 |
March 30, 2010 |
August 6, 2018 |
|
- University Hospital Bonn
Bonn, Germany
|
|
| 72 |
NCT02176408 |
Unknown † |
Efficacy of Adjunctive Exercise for the Behavioral Treatment of Major Depression |
- Major Depressive Disorder
|
- Behavioral: Behavioral Activation
- Behavioral: Exercise Intervention
- Behavioral: Stretching Intervention
|
Interventional
|
Not Applicable |
- Boston University
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Montgomery-Asberg Depression Rating Scale (MADRS)
- Beck Depression Inventory-II (BDI-II)
- Work and Social Adjustment Scale (WSAS)
- (and 8 more...)
|
38 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02176408 |
F31MH100773-01A1 |
|
June 2014 |
June 2016 |
June 2016 |
June 27, 2014 |
April 6, 2016 |
|
- Boston University
Boston, Massachusetts, United States
|
|
| 73 |
NCT01357083 |
Completed |
The Study of Serum Melatonin Rhythm Levels in Patients With Major Depressive Disorder |
- Major Depressive Disorder
|
|
Observational
|
|
- Science & Research Islamic Azad University Branch Khozestan
|
Other |
- Observational Model: Case Control
- Time Perspective: Retrospective
|
- Depression status(measured by Beck depression inventory (BDII-II))
- Measurements of morning and nocturnal melatonin levels by ELISA kit (cat no. RE54021) from the IBL-Hamburg.
|
92 |
All |
22 Years to 48 Years (Adult) |
NCT01357083 |
9460
CCT-NAPN-21087 |
|
August 2010 |
October 2010 |
October 2010 |
May 20, 2011 |
May 20, 2011 |
|
- Shahnaz Khaleghipour
Isfahan, Iran, Islamic Republic of
|
|
| 74 |
NCT02078258 |
Unknown † |
Attention Bias Modification Treatment for Major Depression Disorder in Adolescents |
- Major Depressive Disorder, Single Episode, Unspecified
|
- Behavioral: dot-probe task
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Changes in depressive symptom number measured by the construct interview of the Schedule for Affective Disorders and Schizophrenia for School-Age Children(K-SADS)
- Changes in depressive severity measured by the construct interview of the Schedule for Affective Disorders and Schizophrenia for School-Age Children(K-SADS)
- Self-report symptoms measured by the Center for Epidemiologic Studies Depression Scale (CES-D), State-Trait Anxiety Inventory-Trait(STAI-T)，Rumination Response Style（RRS)，Suicidal Ideation Questionnaire（SIQ）
- Diagnostic status of major depressive disorder assessed by the diagnostic interview of the Schedule for Affective Disorders and Schizophrenia for School-Age Children
|
45 |
All |
11 Years to 19 Years (Child, Adult) |
NCT02078258 |
1 |
|
September 2012 |
September 2014 |
September 2014 |
March 5, 2014 |
August 21, 2014 |
|
- Department of Psychology, Hunan Normal University
Changsha, Hunan, China
|
|
| 75 |
NCT01377194 |
Completed
Has Results |
Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Levomilnacipran ER
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score - Mixed-effects Model for Repeated Measures (MMRM) Analysis.
- Change in Sheehan Disability Scale (SDS) Total Score
|
568 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT01377194 |
LVM-MD-10 |
|
June 2011 |
March 2012 |
March 2012 |
June 21, 2011 |
October 29, 2013 |
October 29, 2013 |
- Forest Investigative Site 039
Birmingham, Alabama, United States - Forest Investigative Site 037
Beverly Hills, California, United States - Forest Investigative Site 012
Encino, California, United States - (and 48 more...)
|
|
| 76 |
NCT01416220 |
Completed |
Lithium Versus Paroxetine in Major Depression |
- Major Depressive Disorder
|
- Drug: Lithium
- Drug: Paroxetine
|
Interventional
|
Phase 4 |
- Nova Scotia Health Authority
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Montgomery Asberg Depression Rating Scale (MADRS)
- The Young Mania Rating Scale (YMRS)
- The Clinical Global Impression (CGI)
- (and 3 more...)
|
2 |
All |
18 Years and older (Adult, Older Adult) |
NCT01416220 |
MoodDig-001 |
|
September 2011 |
February 2013 |
February 2013 |
August 12, 2011 |
February 13, 2015 |
|
- Queen Elizabeth II Health Sciences Centre
Halifax, Nova Scotia, Canada
|
|
| 77 |
NCT00289484 |
Unknown † |
A Study of Omega-3 as an Augmentor of Antidepressant Treatment for Major Depression |
|
- Drug: Omega-3 Polyunsaturated Fatty Acids
|
Interventional
|
Phase 2 |
- The University of New South Wales
- Your Health Inc.
- Sphere Healthcare
- Ocean Nutrition
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Change form pretreatment score on Depression Rating scale at 4 weeks
- Daily mood rating
- Weekly measure of depression
- (and 2 more...)
|
52 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00289484 |
05156 |
|
February 2006 |
|
|
February 9, 2006 |
September 13, 2006 |
|
- The University of New South Wales/Black Dog Institute
Sydney, New South Wales, Australia
|
|
| 78 |
NCT00705185 |
Completed |
Exploring a Potential Blood Test to Diagnose Major Depressive Disorder |
- Major Depressive Disorder
|
|
Observational
|
|
- Massachusetts General Hospital
- Precision Human Biolaboratories
- Cambridge Health Alliance
- (and 3 more...)
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- 16 Biological Markers; Group comparison between adults with Major Depressive Disorder and healthy controls
|
120 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00705185 |
2007-P-002525 |
Bio-TestMDD |
April 2008 |
June 2010 |
June 2010 |
June 25, 2008 |
June 8, 2010 |
|
- University of Connecticut Health Center
Farmington, Connecticut, United States - Psychiatric Medicine Associates, L.L.C.
Chicago, Illinois, United States - Massachusetts General Hosptial
Boston, Massachusetts, United States - (and 2 more...)
|
|
| 79 |
NCT01399671 |
Completed |
Study of the Effectiveness of Vestibular Stimulation as a Coadjuvant Treatment in Major Depression |
- Depression
- Major Depression
- Vestibular Disorders
|
- Other: vestibular stimulation
|
Interventional
|
Not Applicable |
- Fuerza Aérea de Chile
- Pontificia Universidad Catolica de Chile
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hamilton depression rating score
|
80 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01399671 |
SA10I220044 |
|
March 2011 |
January 2012 |
January 2012 |
July 22, 2011 |
March 5, 2012 |
|
- Centro de Medicina Aeroespacial
Santiago, Región Metropolitana, Chile
|
|
| 80 |
NCT01210651 |
Completed
Has Results |
Treating Major Depression With Yoga: A Prospective, Randomized Controlled Pilot Trial |
|
- Behavioral: Hatha Yoga Practice Group
- Behavioral: Attention Control Education Group
|
Interventional
|
Not Applicable |
- University of California, San Francisco
- Mental Insight Foundation
- Pritzker Family Foundation
- Mount Zion Health Fund
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Intent-to-Treat Analysis of Adjusted Mean Beck Depression Inventory-II Scores Over Intervention Period
- Total Change Scores on Beck Depression Inventory-II Among Study Completers
- Number of Study Completers With Remitted Depression, Per Completers Analysis of BDI Scores at 8 Weeks
- (and 2 more...)
|
38 |
All |
14 Years and older (Child, Adult, Older Adult) |
NCT01210651 |
H49362-35940-01 |
|
May 2010 |
January 2011 |
January 2011 |
September 28, 2010 |
January 11, 2017 |
January 11, 2017 |
- University of California San Francisco
San Francisco, California, United States
|
|
| 81 |
NCT01574742 |
Unknown † |
Open Study Assessing the Feasibility of Minocycline in Patients With Unipolar Depression |
|
|
Interventional
|
Phase 1 |
- Shalvata Mental Health Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Depression symptoms
- Depression symptoms - CGI
- depression symptoms - (QIDS-SR)
- (and 2 more...)
|
30 |
All |
18 Years to 68 Years (Adult, Older Adult) |
NCT01574742 |
0007-12-SHA |
|
June 2012 |
June 2014 |
June 2014 |
April 10, 2012 |
July 4, 2012 |
|
- Shalvata Medical Health Center
Hod-HaSharon, Israel
|
|
| 82 |
NCT02484456 |
Recruiting |
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder |
|
- Drug: AV 101 (4-Chlorokynurenine)
- Other: Placebo
|
Interventional
|
Phase 2 |
- National Institute of Mental Health (NIMH)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change from baseline in the Hamilton Depression Rating scale total score.
- Change from baseline in BPRS, CADSS, C-SSRS, HAM-A, HDRS, MADRS, PANAS, SHAPS, SSI, TEPS, YMRS total scores.
- Change from baseline in the C-SSRS total score.
- (and 3 more...)
|
25 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02484456 |
150151
15-M-0151 |
|
June 19, 2015 |
December 31, 2019 |
December 31, 2019 |
June 29, 2015 |
July 6, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 83 |
NCT01469377 |
Completed
Has Results |
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Placebo
- Drug: Cariprazine
|
Interventional
|
Phase 2 |
- Forest Laboratories
- Gedeon Richter Ltd.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 8
- Change From Baseline in the Sheehan Disability Scale (SDS) Total Score at Week 8
|
819 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01469377 |
RGH-MD-75 |
|
December 15, 2011 |
December 12, 2013 |
December 12, 2013 |
November 10, 2011 |
May 1, 2018 |
May 1, 2018 |
- Forest Investigative Site 077
Garden Grove, California, United States - Forest Investigative Site 019
National City, California, United States - Forest Investigative Site 039
Oceanside, California, United States - (and 69 more...)
|
|
| 84 |
NCT02709668 |
Completed |
B Vitamins in MTHFR Positive Patients With Major Depression: A Post Hoc Analysis of Findings |
|
- Dietary Supplement: Enlyte
- Other: placebo
|
Interventional
|
Phase 4 |
- High Point Regional Health Systems
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
|
- Homocysteine levels
- Montgomery Asberg Depression Rating Scale
|
330 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT02709668 |
AMBFDepression |
BVMD |
August 2013 |
April 2014 |
April 2014 |
March 16, 2016 |
March 29, 2016 |
|
|
|
| 85 |
NCT00759395 |
Completed
Has Results |
Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD) |
- Anxious Major Depressive Disorder
|
- Drug: AZD2327
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Hamilton Rating Scale for Depression (HAM-D) Total Score.
- Hamilton Rating Scale for Anxiety (HAM-A) Total Score.
- Psychic Anxiety Item of the Hamilton Rating Scale for Depression (HAM-D).
- (and 2 more...)
|
22 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00759395 |
D0880C00021 |
|
January 2009 |
October 2011 |
October 2011 |
September 25, 2008 |
November 8, 2012 |
November 8, 2012 |
- Research Site
Baltimore, Maryland, United States
|
|
| 86 |
NCT00460902 |
Completed |
Evaluation of the Deep TMS H-Coil in the Treatment of Major Depression- Augmentation of Antidepressant Medication |
|
- Device: Transcranial Magnetic Stimulation (TMS)
|
Interventional
|
Phase 1
Phase 2 |
- Hadassah Medical Organization
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- HAMILTON RATING SCALE FOR DEPRESSION 24 items
|
57 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT00460902 |
395/3.11.06(HMO) |
|
April 2007 |
August 2009 |
August 2009 |
April 17, 2007 |
March 20, 2015 |
|
- Beer Yaacov Medical Center
Beer Yaacov, Israel - Biological psychiatry unit, Psychiatric ward, Hadassah Medical organization
Jerusalem, Israel
|
|
| 87 |
NCT01999010 |
Completed |
Mental Health Telemetry for Self-Management in Major Depression |
- Major Depressive Disorder
|
|
Interventional
|
Not Applicable |
- Sunnybrook Health Sciences Centre
- Canadian Institutes of Health Research (CIHR)
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in self-management ratings
- Change in Quality-of-life (QoL) ratings
|
27 |
All |
14 Years and older (Child, Adult, Older Adult) |
NCT01999010 |
186-2013 |
MHTV |
November 2014 |
April 2016 |
April 2016 |
December 3, 2013 |
January 5, 2017 |
|
- Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
|
|
| 88 |
NCT03653858 |
Recruiting |
Efficacy Study of Deep Brain Stimulation in Patients With Treatment Resistant Major Depression |
- Treatment-resistant Depression
|
- Device: Vercise GEVIA deep brain stimulation (DBS) system
|
Interventional
|
Not Applicable |
- University Hospital Freiburg
- Boston Scientific Corporation
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Montgomery-Asberg Depression Rating Scale (MADRS) total score
- Time to Montgomery-Asberg Depression Rating Scale (MADRS) augmentation of >5 points or clinical worsening in two consecutive visits after DBS termination
- Assessment of (Serious) Adverse Events related to Investigational Medical Device and / or surgical procedures
- (and 31 more...)
|
47 |
All |
20 Years to 75 Years (Adult, Older Adult) |
NCT03653858 |
P000767
DRKS00014947
CIV-17-07-020746 |
FORESEE III |
September 3, 2018 |
June 2, 2022 |
June 2, 2023 |
August 31, 2018 |
September 20, 2018 |
|
- University Hospital Freiburg
Freiburg, Baden-Württemberg, Germany - University Hospital Bonn
Bonn, Nordrhein-Westfalen, Germany
|
|
| 89 |
NCT00101452 |
Completed
Has Results |
Safety and Effectiveness of S-adenosyl-l-methionine (SAMe) for the Treatment of Major Depression |
|
- Drug: S-adenosyl-l-methionine
- Drug: Escitalopram
- Drug: Placebo
|
Interventional
|
Not Applicable |
- Maurizio Fava, MD
- National Center for Complementary and Integrative Health (NCCIH)
- Massachusetts General Hospital
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Hamilton Rating Scale for Depression (HAM-D)
|
199 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT00101452 |
R01AT001638-01A1 |
|
April 2005 |
June 2010 |
June 2010 |
January 11, 2005 |
April 4, 2017 |
December 31, 2012 |
- Massachusetts General Hospital
Boston, Massachusetts, United States - Butler Hospital
Providence, Rhode Island, United States
|
|
| 90 |
NCT01244724 |
Terminated
Has Results |
Lexapro for Major Depression in Patients With Epilepsy |
|
|
Interventional
|
Phase 4 |
- Weill Medical College of Cornell University
- Forest Laboratories
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Hamilton Depression Scale
- National Hospital Seizure Severity Scale
|
26 |
All |
18 Years and older (Adult, Older Adult) |
NCT01244724 |
LXP-MD-109 |
|
October 2007 |
December 2011 |
March 2012 |
November 19, 2010 |
July 11, 2018 |
August 3, 2015 |
- Weill Medical College of Cornell University
New York, New York, United States
|
|
| 91 |
NCT00704860 |
Completed |
Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism |
|
- Other: Open label pharmacotherapy
|
Interventional
|
Phase 4 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Sustained Remission from Depression and Hippocampal Atrophy
- 5-HT1a Genetic Markers
|
27 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00704860 |
REB- 200506 |
|
February 2005 |
November 2009 |
December 2010 |
June 25, 2008 |
January 19, 2011 |
|
- University of Ottawa Institute of Mental Health Research
Ottawa, Ontario, Canada
|
|
| 92 |
NCT01464463 |
Completed |
The Impact of Psychological Interventions on Psychometric and Immunological Measures in Patients With Major Depression |
|
- Behavioral: CBT - active
- Behavioral: CBT - euthymic
- Behavioral: CBASP
|
Interventional
|
Phase 3 |
- Philipps University Marburg Medical Center
- Universität Duisburg-Essen
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Changes in severity of depressive symptoms from baseline (beginning of therapy) to 4 weeks after baseline, to 8 weeks after baseline, to 16 weeks after baseline (end of therapy) to 6-month-follow up
- Changes in immunological measures from baseline (beginning of therapy) to 4 weeks after baseline, to 8 weeks after baseline, to 16 weeks after baseline (end of therapy) to 6-month-follow up
- Changes in psychopathological variables from baseline (beginning of therapy) to 4 weeks after baseline, to 8 weeks after baseline, to 16 weeks after baseline (end of therapy) to 6-month-follow up
- (and 3 more...)
|
200 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01464463 |
DFG RI 574/23-1 |
|
August 2011 |
April 2016 |
|
November 3, 2011 |
June 10, 2016 |
|
- Department of Clinical Psychology and Psychotherapy, Philipps University Marburg
Marburg, Germany
|
|
| 93 |
NCT01175616 |
Withdrawn |
Creatine Augmentation in Veterans With SSRI-Resistant Major Depression |
- Major Depressive Disorder
|
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Montgomery-Asberg Depression Rating Scale (MADRS) Score
- Changes in 3T 31Phosphorus Magnetic Resonance Spectroscopy metabolites
|
0 |
All |
18 Years to 55 Years (Adult) |
NCT01175616 |
00041936 |
|
September 2012 |
April 2014 |
April 2014 |
August 5, 2010 |
August 15, 2016 |
|
|
|
| 94 |
NCT00744406 |
Completed |
Patient Dimensions as Predictors of Varied Treatment Responses and Outcomes in Patients With Major Depression |
- Depression
- Major Depressive Disorder
|
- Behavioral: Cognitive Behavioral Therapy
- Behavioral: Interpersonal Therapy
- Drug: Antidepressant medication (sertraline ,paroxetineor or venlafaxine)
|
Interventional
|
Phase 2 |
- Centre for Addiction and Mental Health
- Ontario Mental Health Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Hamilton Depression Rating Scale
|
72 |
All |
18 Years to 60 Years (Adult) |
NCT00744406 |
160/2001 |
|
July 2003 |
September 2006 |
|
September 1, 2008 |
September 1, 2008 |
|
- Centre for Addiction and Mental Health
Toronto, Ontario, Canada
|
|
| 95 |
NCT00368303 |
Completed |
A Local Register Study For Major Depression Of Paroxetine Controlled Release |
- Depressive Disorder, Major
- Major Depressive Disorder (MDD)
|
- Drug: Paroxetine CR
- Drug: Paroxetine IR
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Scores on depression rating scale at treatment week 1,2,3,4,6 and 8.
- Scores on clinical impression severity and improvement items at treatment week 1, 2,3,4,6,8
|
362 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00368303 |
PCR103124 |
|
December 2006 |
|
|
August 24, 2006 |
June 4, 2012 |
|
- GSK Investigational Site
Guangzhou, Guangdong, China - GSK Investigational Site
Baoding, Hebei, China - GSK Investigational Site
Changsha, Hunan, China - (and 8 more...)
|
|
| 96 |
NCT00420004 |
Completed
Has Results |
A Study for Participants With Major Depression |
- Major Depressive Disorder
|
- Drug: LY2216684
- Drug: Placebo
- Drug: Escitalopram
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline to Week 8 in the 17-item Hamilton Depression Rating Scale (HAMD-17) Total Score
- Change From Baseline to Week 8 in Maier-Philipp Subscale of the 17-item Hamilton Depression Rating Scale (HAMD-17)
- Response and Remission Rates
- (and 16 more...)
|
469 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00420004 |
11174
H9P-MC-LNBD |
|
December 2006 |
March 2008 |
March 2008 |
January 9, 2007 |
April 27, 2018 |
April 27, 2018 |
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Orlando, Florida, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Prairie Village, Kansas, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Allentown, Pennsylvania, United States - (and 4 more...)
|
|
| 97 |
NCT03556124 |
Recruiting |
Transcranial Direct Current Stimulation in Major Depression |
- Major Depressive Disorder
|
- Device: Active - HD tDCS
- Device: Sham - HD tDCS
- Device: Active - Conventional tDCS
- Device: Sham - Conventional tDCS
|
Interventional
|
Not Applicable |
- University of California, Los Angeles
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Changes in non-invasive MRI measures of cerebral blood flow between baseline and end of treatment
- Change in non-invasive MRI measures of current flow
|
60 |
All |
18 Years to 55 Years (Adult) |
NCT03556124 |
17-000779
R61MH110526 |
|
February 2, 2018 |
July 31, 2022 |
July 31, 2022 |
June 14, 2018 |
June 14, 2018 |
|
- University of California, Los Angeles (UCLA)
Los Angeles, California, United States
|
|
| 98 |
NCT00177996 |
Completed |
Pharmacotherapy in Depression With Panic Spectrum |
|
- Drug: sertraline hydrochloride
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Treatment
|
- Somatic Symptoms Scale (SSC)
- Hamilton Rating Scale For Depression- 25 item (HRSD 25)
- Global Assessment of Functioning (GAF)
|
30 |
All |
18 Years to 60 Years (Adult) |
NCT00177996 |
010403 |
|
October 2001 |
January 2007 |
January 2007 |
September 15, 2005 |
January 15, 2016 |
|
- Western Psychiatric Insititue and Clinic
Pittsburgh, Pennsylvania, United States
|
|
| 99 |
NCT01034462 |
Completed
Has Results |
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Levomilnacipran ER
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
- Change in Sheehan Disability Scale (SDS) Total Score
|
442 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT01034462 |
LVM-MD-03 |
|
December 2009 |
December 2011 |
December 2011 |
December 17, 2009 |
October 25, 2013 |
October 25, 2013 |
- Forest Investigative Site 055
Dothan, Alabama, United States - Forest Investigative Site 065
Highlands Ranch, Colorado, United States - Forest Investigative Site 057
Boca Raton, Florida, United States - (and 20 more...)
|
|
| 100 |
NCT00517764 |
Completed |
Childhood Adversity, Genetic Polymorphisms and Stress in First Onset Major Depression |
|
|
Interventional
|
Not Applicable |
- Centre for Addiction and Mental Health
- Queen's University
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Hamilton Rating Scale for Depression (HRDS)
|
299 |
All |
16 Years to 29 Years (Child, Adult) |
NCT00517764 |
155/2006 |
|
December 2006 |
June 2013 |
June 2013 |
August 17, 2007 |
August 9, 2013 |
|
- Queens University
Kingston, Ontario, Canada - Centre for Addiction and Mental Health
Toronto, Ontario, Canada
|
|
Create an RSS feed from your search for:
Download the search results for: